PA
KURA icon

Profund Advisors’s Kura Oncology KURA Stock Holding History

Profund Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476K Sell
43,346
-16,572
-28% -$156K 0.01% 576
2026
Q1 		$487K Sell
59,918
-9,206
-13% -$79.1K 0.02% 557
2025
Q4 		$718K Buy
69,124
+44,289
+178% +$465K 0.02% 441
2025
Q3 		$220K Buy
24,835
+2,478
+11% +$17.7K 0.01% 926
2025
Q2 		$129K Sell
22,357
-4,967
-18% -$30.4K ﹤0.01% 950
2025
Q1 		$180K Sell
27,324
-1,034
-4% -$8.06K 0.01% 918
2024
Q4 		$247K Buy
28,358
+9,490
+50% +$137K 0.01% 874
2024
Q3 		$369K Sell
18,868
-4,699
-20% -$95.2K 0.01% 685
2024
Q2 		$485K Sell
23,567
-25,115
-52% -$516K 0.02% 507
2024
Q1 		$1.04M Buy
48,682
+23,094
+90% +$449K 0.04% 349
2023
Q4 		$368K Sell
25,588
-14,033
-35% -$138K 0.02% 676
2023
Q3 		$361K Buy
39,621
+3,228
+9% +$32.8K 0.02% 573
2023
Q2 		$385K Sell
36,393
-14,779
-29% -$175K 0.02% 593
2023
Q1 		$626K Buy
+51,172
New +$639K 0.04% 437

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Profund Advisors's KURA Position: Q2 2026 in Review

Profund Advisors reduced its Kura Oncology (KURA) stake by 28% in Q2 2026, selling an estimated $156K and leaving 43,346 shares worth $476K. The position accounts for 0.01% of the portfolio, ranked #576.

Profund Advisors first reported a position in KURA in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.04M in Q1 2024. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Profund Advisors held 43,346 shares of Kura Oncology worth $476K as of Q2 2026.
  • Profund Advisors sold 16,572 Kura Oncology shares in Q2 2026, an estimated $156K.
  • Kura Oncology made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #576 holding.
  • Profund Advisors first reported a position in Kura Oncology in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Kura Oncology position peaked at $1.04M in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.